Epinephrine is a small molecule commercialized by Aquestive Therapeutics, with a leading Phase III program in Anaphylaxis. According to Globaldata, it is involved in 13 clinical trials, of which 8 were completed, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Epinephrine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Epinephrine is expected to reach an annual total of $687 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Epinephrine Overview
Epinephrine (AQST-109) is under development for the treatment of allergic reactions including anaphylaxis. It is administered through sublingual route as film. The drug candidate is being developed based on PharmFilm technology.
Aquestive Therapeutics Overview
Aquestive Therapeutics (Aquestive) is a Pharmaceutical company that offers drug products. The company offers products that include sympazan, a film formulation of clobazamor for treating seizures associated with Lennox-Gastaut syndrome (LGS); suboxone for the treatment of opioid dependence; zuplenz for the treatment of nausea and vomiting; and diazepam. It also provides nutraceuticals, packaging solutions and consumer products. Aquestive provides PharmFilm, a drug delivery platform that delivers existing prescription products directly to the bloodstream. The company collaborates with other pharmaceutical companies for the development and commercialization of its pharmaceutical products. The company has a manufacturing facility in Indiana, the US. Aquestive Therapeutics is headquartered in Warren, New Jersey, the US
The company reported revenues of (US Dollars) US$50.6 million for the fiscal year ended December 2023 (FY2023), an increase of 6.1% over FY2022. The operating loss of the company was US$16.5 million in FY2023, compared to an operating loss of US$42.1 million in FY2022. The net loss of the company was US$7.9 million in FY2023, compared to a net loss of US$54.4 million in FY2022.
For a complete picture of Epinephrine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
